CD4 and colitis: After a preliminary validation of the ability of anti-LAP antibody administration to selectively deplete LP CD4+LAP+cell without affecting the % of LP CD4+Foxp3+ cells (Supplementary Figure 2), we administered the antibody or its isotype control in two groups of mice, before the induction of oxazolone colitis.